However, cell-type and patient-specific responses identified by MAM, such as bioactive metabolites demonstrating enhanced activity against a FLT3-ITD AML sample and selective activity for leukemia cells (e.g., well 24, m/z = 1054, Fig. 3), demonstrate the potential of this platform for performing preliminary analysis and prioritization of activity differences within a natural product family for common AML subclasses. This evidence concerns the gene FLT3 and leukemia.